Lumeon partners with Medtronic on value-based care - Gilde Healthcare

Lumeon partners with Medtronic on value-based care

4. Dezember 2019

Utrecht (the Netherlands) and London, (UK) – Lumeon, the leader in Care Pathway Management (CPM), today announced that it has entered a strategic partnership with Medtronic, a global leader in medical technology, services, and solutions, that will support Medtronic’s European healthcare provider customers in their transition to efficient, value-based care models.

Through the partnership, Medtronic’s Integrated Healthcare Solutions (IHS) business will leverage Lumeon’s leading CPM Platform to operationalise care pathways for surgery optimization and chronic disease management. These pathways allow providers to create more effective care coordination that reduces the cost of care delivery while minimising unwarranted variation in care.

Medtronic IHS aims to enhance the efficiency and effectiveness of patient care settings, such as cardiac catheterisation labs and operating rooms, while optimising patient pathways and care delivery from the time a patient is referred for treatment to the time he or she has fully recovered.

“As the global healthcare market undergoes a transition from activity-based reimbursement to outcome-based reimbursement, providers are faced with the challenge of reinventing their business models while delivering care that ensures high-quality clinical, operational, and financial outcomes,” said Robbie Hughes, founder and CEO at Lumeon. “We are proud to be working with Medtronic, a company with a well-earned reputation in value-based care models, to help providers master that transition.”

“We are partnering with over 100 hospitals in Europe to develop evidence-based, best practice-informed pathways that deliver superior outcomes for the lowest possible cost,” said Frederic Noël, vice president, Medtronic IHS EMEA. “To help our customers embed these pathways in daily practice and apply them at scale, across their patient groups, we need more than pathway reference models and change management services. We must provide them with solutions to digitalise the pathway, and automate and orchestrate multi-disciplinary care delivery, leveraging Lumeon’s CPM platform.”

Lumeon’s CPM platform ensures that every patient stays on a personalised plan of care throughout his or her entire healthcare journey. It leverages intelligent automation and orchestration to manage a shared plan of care across multiple teams and settings, automatically adjusting activities and deploying the right resource required for each individual patient in real-time.

 

About Lumeon
Lumeon provides Care Pathway Management (CPM) solutions for healthcare organizations. Its industry-leading platform combines evidence-based pathways with deep operational expertise to deliver better care at lower cost.
A patient-first approach to pathway design, orchestration and automation ensures healthcare provider resources are optimized to deliver superior outcomes at less cost, achieving the goals of new reimbursement models.
Progressive health systems in the USA and Europe have deployed Lumeon’s multi-award winning platform across more than 2,000 care locations. For more information, visit the company’s website at www.lumeon.com

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing € 1 billion ($ 1.2 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare company ProVerum Announces Completion of Enrollment for the ProVIDE Clinical Study for BPH and First-use of its New Flexible, Steerable Delivery System

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor's office, today announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate...
21. März 2024

Gilde Healthcare veräussert RAD-x an ein konsortium aus Swiss Life Asset Managers und Vesper Infrastructure Fund I

Gilde Healthcare´s Private Equity Fund (“Gilde Healthcare”), ein auf das Gesundheitswesen spezialisierter Investor, hat eine bindende Vereinbarung über den Verkauf seiner Mehrheitsbeteiligung an RAD-x an ein Konsortium aus Swiss Life Asset Managers und Vesper Next...
18. März 2024

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V.,...
29. Februar 2024